About: Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta
Creator	Brzoska, Josef Hündgen, Manfred Von Eick, Harald
Source	Medline; PMC
abstract	The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 µg for 3–5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.1055/a-1170-4395
bibo:pmid	32443163
has license	no-cc
sha1sum (hex)	6c55af90d666c8d6f7d0ce9d329d52907f7db0aa
schema:url	https://doi.org/10.1055/a-1170-4395
resource representing a document's title	Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta
has PubMed Central identifier	PMC7366041
has PubMed identifier	32443163
schema:publication	Drug Res (Stuttg)
resource representing a document's body	covid:6c55af90d666c8d6f7d0ce9d329d52907f7db0aa#body_text
is schema:about of	named entity 'beta-1a' named entity 'days' named entity 'general' named entity 'analysed' named entity 'viral infections' named entity 'MULTIPLE SCLEROSIS' named entity 'SIDE EFFECTS' named entity 'REGIMEN' named entity 'SUITABLE' named entity 'GENERAL' named entity 'interferon beta-1a' named entity 'The' named entity 'analysed' named entity 'intravenous infusion' named entity 'severe' named entity 'interferons' named entity 'consists' named entity 'intravenous infusion' named entity 'interferon beta' named entity 'autoimmunity' named entity 'coronaviruses' named entity 'mode of action' named entity 'virus replication' named entity 'animal species' named entity 'human cell cultures' named entity 'IV infusion' named entity 'cell culture' named entity 'viral pneumonia' named entity 'recombinant' named entity 'interferon alfa' named entity 'SARS' named entity 'leukopenia' named entity 'interferon beta-1a' named entity 'interferon beta' named entity 'interferon beta' named entity 'serum levels' named entity 'life-threatening' named entity 'cellular immune' named entity 'coronavirus infections' named entity 'viral infections' named entity 'interferons' named entity 'viral infections' named entity 'COVID-19' named entity 'MTD' named entity 'pneumonia' named entity 'intravenous' named entity 'interferon' named entity 'lung' named entity 'herpes simplex' named entity 'CHO' named entity 'humoral' named entity 'topical application' named entity 'interferon alpha' named entity 'interferon beta' named entity 'interferon' named entity 'World Health Organization' named entity 'cytokine' named entity 'host cells' named entity 'interferon' named entity 'interferon alpha' named entity 'Rebif' named entity 'serum' named entity 'MERS' named entity 'immune status' named entity 'immune-compromised' named entity 'interferon' named entity 'route of administration' named entity 'chronic viral hepatitis' named entity 'interferon beta' named entity 'serum levels' named entity 'interferon beta-1a' named entity 'interferon beta-1b' named entity 'interferon' named entity 'protein structures' named entity 'interferon' named entity 'coronavirus' named entity 'immune disorders' named entity 'multiple sclerosis' named entity 'physiological'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software